Similarly, we also confirmed differential expression for noncoding genes, like PCA3, the first clinically approved lncRNA marker for PCa (Bussemakers et al. 1999; de Kok et al. 2002), PCAT1, a prostate-specific lncRNA involved in disease progression (Prensner et al. 2011), MALAT1, which is associated with PCa poor prognosis (Ren et al. 2013), CDKN2B-AS1, an antisense lncRNA up-regulated in PCa that inhibits tumor suppressor genes activity (Kotake et al. 2011; Gutschner and Diederichs 2012), and the MIR135 host gene, which is associated with castration-resistant PCa (Huang et al. 2015). The gene discussed is PCAT1; the disease is posterior cortical atrophy.